Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23805618 | 1.00 | GRIN2B (0.62) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL23805595 | 1.00 | GRIN2B (0.62) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL23805590 | 0.83 | GRIN2B (0.63) | GRIN2BGRIN2AGRIN1 | |
| SCHEMBL23805563 | 0.83 | GRIN2B (0.63) | GRIN2BGRIN2AGRIN1 | |
| SCHEMBL18629617 | 0.82 | GRIN2B (0.59) | GRIN2BGRIN2A | |
| SCHEMBL23805644 | 0.81 | GRIN2B (0.62) | GRIN2BGRIN2AGRIN1 | |
| SCHEMBL30076104 | 0.80 | GRIN2B (0.63) | GRIN2BGRIN2AGRIN1GRIN2DGRIN3B | |
| SCHEMBL22701642 | 0.80 | GRIN2B (0.65) | GRIN2BGRIN2AGRIN1 | |
| SCHEMBL20090933 | 0.77 | GRIN1 (0.62) | GRIN2BGRIN1 | |
| SCHEMBL16600965 | 0.76 | GRIN2B (1.00) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | CADENT THERAPEUTICS, INC (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116749-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | GRIN2B 4/4885GRIN2A 1/4885GRIN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.